Enjuvia is a drug owned by Aspen Pharma Usa Inc. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 08, 2021. Details of Enjuvia's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6660726 | Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same |
Mar, 2021
(3 years ago) |
Expired
|
| US6855703 | Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
Feb, 2021
(3 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Enjuvia's patents.
Latest Legal Activities on Enjuvia's Patents
Given below is the list of recent legal activities going on the following patents of Enjuvia.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Post Issue Communication - Certificate of Correction | 12 May, 2004 | US6660726 |
| Patent Issue Date Used in PTA Calculation Critical | 09 Dec, 2003 | US6660726 |
| Recordation of Patent Grant Mailed Critical | 09 Dec, 2003 | US6660726 |
| Issue Notification Mailed Critical | 20 Nov, 2003 | US6660726 |
| Receipt into Pubs | 27 Oct, 2003 | US6660726 |
| Mail Response to 312 Amendment (PTO-271) Critical | 23 Oct, 2003 | US6660726 |
| Application Is Considered Ready for Issue Critical | 23 Oct, 2003 | US6660726 |
| Response to Amendment under Rule 312 Critical | 23 Oct, 2003 | US6660726 |
| Receipt into Pubs | 20 Oct, 2003 | US6660726 |
| Workflow - File Sent to Contractor | 25 Aug, 2003 | US6660726 |
While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Enjuvia and ongoing litigations to help you estimate the early arrival of Enjuvia generic.
Enjuvia's Litigations
Enjuvia been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Mar 12, 2003, against patent number US6855703. The petitioner , challenged the validity of this patent, with Edward N Hill et al as the respondent. Click below to track the latest information on how companies are challenging Enjuvia's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US6855703 | March, 2003 |
Decision
(11 Feb, 2004) | Edward N Hill et al | |
US patents provide insights into the exclusivity only within the United States, but Enjuvia is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Enjuvia's family patents as well as insights into ongoing legal events on those patents.
Enjuvia's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Enjuvia's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 08, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Enjuvia Generics:
There are no approved generic versions for Enjuvia as of now.
Alternative Brands for Enjuvia
Enjuvia which is used for managing symptoms of menopause, including vaginal dryness, pain during intercourse, and vasomotor symptoms., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Apil |
| |||
| Duchesnay |
| |||
| Sebela Ireland Ltd |
| |||
| Wyeth Pharms |
| |||
About Enjuvia
Enjuvia is a drug owned by Aspen Pharma Usa Inc. It is used for managing symptoms of menopause, including vaginal dryness, pain during intercourse, and vasomotor symptoms. Enjuvia uses Estrogens, Conjugated Synthetic B as an active ingredient. Enjuvia was launched by Aspen in 2004.
Approval Date:
Enjuvia was approved by FDA for market use on 20 December, 2004.
Active Ingredient:
Enjuvia uses Estrogens, Conjugated Synthetic B as the active ingredient. Check out other Drugs and Companies using Estrogens, Conjugated Synthetic B ingredient
Treatment:
Enjuvia is used for managing symptoms of menopause, including vaginal dryness, pain during intercourse, and vasomotor symptoms.
Dosage:
Enjuvia is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.45MG | TABLET | Discontinued | ORAL |
| 1.25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |
| 0.3MG | TABLET | Discontinued | ORAL |
| 0.9MG | TABLET | Discontinued | ORAL |
| 0.625MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | TABLET | Discontinued | ORAL |